What is Foundayo?
Foundayo is a tablet with the active ingredient orforglipron from pharmaceutical company Eli Lilly. It is intended for weight management in adults with obesity, or with overweight and at least one weight-related condition, in combination with a calorie-restricted diet and increased physical activity. Foundayo has been approved in the United States (April 2026) and the United Kingdom (August 2026). The drug is not yet registered in the Netherlands. You can find more about our medical approach in our treatment program.
Orforglipron (oral)
Orforglipron is a GLP-1 receptor agonist. It is a small, non-peptide molecule, allowing it to be taken as a regular tablet. This is the difference with semaglutide in tablet form, which must be taken on an empty stomach and with a strict time window. Foundayo can be taken at any time of the day, with or without food and drink.
Foundayo for overweight and obesity
Foundayo is used as an adjunct to diet and exercise to reduce excess body weight and maintain achieved weight. In the UK, this applies to adults with a BMI of 30 or higher, or a BMI of 27 to 30 with at least one weight-related condition, such as high blood pressure, elevated cholesterol, or sleep apnea. Additionally, it has been approved in the UK to improve blood sugar in inadequately controlled type 2 diabetes.

